Plasma Stability
Testing

Blood plasma is a hostile environment for peptides. It contains a diverse array of proteases—including aminopeptidases, carboxypeptidases, endopeptidases, and dipeptidyl peptidases—that have evolved specifically to break down circulating peptides and proteins. Linear peptides composed of natural L-amino acids are particularly vulnerable because they are recognized and cleaved by multiple protease families simultaneously.

The practical consequence is that most unmodified therapeutic peptides have plasma half-lives measured in minutes, not hours. A peptide that shows potent target binding in a biochemical assay may have negligible in vivo activity if it is degraded before reaching its target. Understanding the rate and sites of proteolytic cleavage is therefore essential for designing peptides with sufficient metabolic stability to be therapeutically useful.

Plasma stability testing involves incubating a known concentration of peptide in fresh plasma (typically human, mouse, or rat, depending on the species relevant to your program) at 37 °C. Aliquots are removed at defined time points—commonly 0, 15, 30, 60, 120, and 240 minutes—and the reaction is quenched by protein precipitation with organic solvent. The supernatant is analyzed by LC-MS/MS to quantify remaining intact peptide at each time point.

Plotting peptide concentration versus time yields a degradation curve, from which the half-life (t½) is calculated. Most peptides follow first-order degradation kinetics in plasma, so the half-life can be derived from a simple exponential fit. Species-specific differences are common: a peptide may be stable in human plasma but rapidly degraded in mouse plasma due to differences in protease repertoire, which has direct implications for translating preclinical pharmacokinetic data to human predictions.

Plasma stability data bridges the gap between in vitro potency and in vivo performance. A peptide with a 5-minute plasma half-life will require either very high doses, frequent dosing, or structural modifications to achieve therapeutic exposure. Common stabilization strategies include incorporation of D-amino acids at susceptible cleavage sites, backbone N-methylation, cyclization to protect termini, and conjugation to half-life extension moieties such as PEG, albumin-binding domains, or fatty acids. Plasma stability testing before and after these modifications quantifies their impact and guides iterative optimization toward a candidate with both potency and metabolic stability.